In silico and in vitro assessment of drugs potentially causing adverse effects by inhibiting CYP17A1

This study combined in silico and in vitro methods to identify drugs inhibiting CYP17A1. The most potent CYP17A1 inhibitors identified are serdemetan, mocetinostat, nolatrexed, liarozole, and talarozole. While some of these drugs are currently under investigation for the treatment of various cancers, their potential for the treatment of prostate cancer is yet to be explored. The DrugBank database was screened for CYP17A1 inhibitors, to increase the awareness for the risk of drug-induced pseudohyperaldosteronism and to highlight drugs so far unknown for their potential to cause side effects resulting from CYP17A1 inhibition.PMID:38688424 | DOI:10.1016/j.taap.2024.116945
Source: Toxicology and Applied Pharmacology - Category: Toxicology Authors: Source Type: research